Current Treatment and Challenge of Coloanal Disorders
A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Surgery".
Deadline for manuscript submissions: closed (20 November 2021) | Viewed by 4489
Special Issue Editor
Special Issue Information
Dear Colleagues,
Amid a flood of information, treatment options for coloanal disorders are growing rapidly. For inflammatory bowel disease (IBD), development of various biologics such as infliximab, adalimumab, and certolizumab pegol, as well as immunomodulators such as azathioprine and 6-Mercaptopurine, has led to improvement in patients’ drug compliance and the prognosis for IBD. As for surgical treatment of colon/rectal diseases, with the rapid development of minimally invasive surgical techniques, particularly for cancer, options for surgical treatment have become diversified including the recent robotic surgeries, thus improving the quality of life of the patients. In particular, the introduction and advancement of robotic surgery have shown oncological results comparable to those of laparoscopic operation, taking into account not only the quality of life of the patients but also the ergonomics of the operator.
Despite the accumulation of such diverse medical knowledge, more medical papers are still needed to establish a global guideline that can be applied to all patients regardless of nationality or race.
Through this Issue, we intend to deal with the contents of coloanal disorder and focus on places with the latest medical opinions covering not only diseases such as IBD but also colon/rectal diseases, including cancer and anal diseases.
Prof. Dr. Seong-taek Oh
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- inflammatory bowel disease
- colon cancer
- rectal cancer
- chemotherapy
- anal disease
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
